Market news — every asset we track

Assets

LPTX

Leap Therapeutics publishes DeFianCe trial results in journal

Aug 12Investing.com

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.

Aug 12Yahoo Finance

LPTX

This is the newest page. Registered accounts read further back.